China approves Pfizer GLP-1 drug for weight loss

By Andrew Silver SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight management in overweight or obese adults, the U.S. drugmaker said on WeChat on Friday, boosting competition in a market analysts expect to be worth billions of dollars. The injection belongs to the class of GLP-1 receptor agonist drugs sold locally by drugmakers such as